Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cassava Sciences Inc SAVA

Healthcare
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of... see more

Recent & Breaking News (NDAQ:SAVA)

New Research Shows Simufilam Suppresses Overactive mTOR

GlobeNewswire June 27, 2023

New Publication Highlights Basic Science Supporting Simufilam

GlobeNewswire June 12, 2023

Cassava Sciences to Present at the Jefferies Global Healthcare Conference

GlobeNewswire June 1, 2023

Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer's Disease

GlobeNewswire May 11, 2023

New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A

GlobeNewswire May 8, 2023

Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates

GlobeNewswire May 1, 2023

Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference

GlobeNewswire April 26, 2023

Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

GlobeNewswire February 28, 2023

Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer's Disease

GlobeNewswire February 8, 2023

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer's Disease

GlobeNewswire January 24, 2023

Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD

GlobeNewswire December 20, 2022

Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer's Disease

GlobeNewswire December 6, 2022

Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

GlobeNewswire November 22, 2022

Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

GlobeNewswire November 18, 2022

CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

Business Wire November 11, 2022

Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates

GlobeNewswire November 7, 2022

Cassava Sciences Files Lawsuit Against Perpetrators of "Short and Distort" Campaign

GlobeNewswire November 3, 2022

CASSAVA SCIENCES INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

PR Newswire October 28, 2022

Cassava Sciences Announces Expansion of Leadership Team

GlobeNewswire October 27, 2022

CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA

Business Wire October 14, 2022